$0.67
5.34% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Cue Biopharma, Inc. Stock price

$0.67
-0.11 14.29% 1M
-0.42 38.57% 6M
-0.42 38.57% YTD
-1.20 64.19% 1Y
-2.63 79.71% 3Y
-28.10 97.67% 5Y
-10.96 94.24% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.04 5.34%
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Key metrics

Market capitalization $50.45m
Enterprise Value $44.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.56
P/S ratio (TTM) P/S ratio 6.31
P/B ratio (TTM) P/B ratio 6.29
Revenue growth (TTM) Revenue growth 13.83%
Revenue (TTM) Revenue $7.99m
EBIT (operating result TTM) EBIT $-41.22m
Free Cash Flow (TTM) Free Cash Flow $-34.88m
Cash position $13.14m
EPS (TTM) EPS $-0.66
P/E forward negative
P/S forward 9.37
EV/Sales forward 8.25
Short interest 1.15%
Show more

Is Cue Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Cue Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Cue Biopharma, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Cue Biopharma, Inc. forecast:

Buy
100%

Financial data from Cue Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.99 7.99
14% 14%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
18% 18%
151%
- Research and Development Expense 35 35
16% 16%
432%
-39 -39
19% 19%
-486%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -41 -41
20% 20%
-516%
Net Profit -41 -41
19% 19%
-508%

In millions USD.

Don't miss a Thing! We will send you all news about Cue Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cue Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments
Neutral
GlobeNewsWire
13 days ago
Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T ce...
Neutral
GlobeNewsWire
16 days ago
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in N...
More Cue Biopharma, Inc. News

Company Profile

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Daniel Passeri
Employees 41
Founded 2014
Website www.cuebiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today